kabutan

Chiome Bioscience Inc.(4583) Summary

4583
TSE Growth
Chiome Bioscience Inc.
99
JPY
0
(0.00%)
Apr 30, 11:29 am JST
0.61
USD
Apr 29, 10:29 pm EDT
Result
PTS
outside of trading hours
98.8
Apr 30, 11:28 am JST
Summary Chart Historical News Financial Result
PER
PBR
6.50
Yield
ー%
Margin Trading Ratio
946.00
Stock Price
Apr 30, 2026
Opening Apr 30, 9:00 am
99 JPY 0.61 USD
Previous Close Apr 28
99 JPY 0.62 USD
High Apr 30, 10:50 am
102 JPY 0.63 USD
Low Apr 30, 9:18 am
97 JPY 0.60 USD
Volume
912,500
Trading Value
0.09B JPY 0.57M USD
VWAP
99.41 JPY 0.62 USD
Minimum Trading Value
9,900 JPY 61 USD
Market Cap
7.19B JPY 0.04B USD
Number of Trades
181
Liquidity & Number of Trades
As of Apr 30, 2026
Liquidity
Mid
1-Year Average
253
1-Year High Jun 3, 2025
2,216
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 0 6,382,500
Apr 17, 2026 0 6,233,900
Apr 10, 2026 0 6,177,400
Apr 3, 2026 0 6,035,800
Mar 27, 2026 0 6,042,900
Company Profile
Chiome Bioscience Inc. is a drug discovery venture originating from RIKEN. The company specializes in proprietary antibody production technology and generates revenue through licensing.
Sector
Pharmaceuticals
Chiome Bioscience Inc. focuses on developing drug candidates for diseases with high unmet medical needs and supporting antibody drug discovery research, utilizing its core proprietary antibody production technology, the ADLib system. The company's main business area covers upstream processes from basic and exploratory research to preclinical development and early clinical development, with a basic strategy of early out-licensing of development candidate antibodies. In its drug discovery support business, Chiome Bioscience Inc. offers protein expression and purification services as well as antibody production services. The company integrates multiple antibody production technologies to maximize its antibody production capabilities. Chiome Bioscience Inc. has several in-house pipelines, including CBA-1205 and CBA-1535, and is actively promoting new drug discovery projects.